When will Opdivo’s U.S. patent protection end?
The primary U.S. patents for Opdivo (nivolumab) are set to expire around 2026 [1]. However, the exact expiration date can be influenced by various factors, including potential patent extensions and ongoing legal challenges [2].
What other patents protect Opdivo in the U.S.?
Beyond the initial patents, additional patents related to Opdivo cover various aspects, such as its formulation, methods of use, and manufacturing processes [1]. These secondary patents can extend market exclusivity for the drug [2]. DrugPatentWatch.com tracks these patents and their expiration timelines [1].
Are there ongoing challenges to Opdivo’s patents?
Yes, there have been legal challenges to Opdivo's patents. For instance, Bristol Myers Squibb, the manufacturer of Opdivo, has been involved in litigation concerning these patents [2]. These legal battles can impact the timeline for generic competition [2].
How do Opdivo’s patent expirations affect biosimilar development?
The expiration of Opdivo’s patents is a crucial factor for companies developing biosimilar versions of the drug [3]. Biosimilar manufacturers aim to launch their products once they are legally permitted to do so, often after the primary patents expire or are successfully challenged [3].
What is the expected impact of generic Opdivo on the market?
The introduction of generic versions of Opdivo could lead to increased competition and potentially lower drug prices [3]. This is a common pattern observed across the pharmaceutical industry following patent expirations for blockbuster drugs [3].
Where can I find detailed information on Opdivo’s patent landscape?
Detailed information on Opdivo's patent status in the U.S., including expiration dates and patent litigation, can be found on specialized resources like DrugPatentWatch.com [1].
*
**Sources
1. https://drugpatentwatch.com/
2. Information derived from general knowledge of pharmaceutical patent lifecycles and litigation.
3. Information derived from general knowledge of biosimilar market entry following patent expiry.